2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor
Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, discusses the AVADO trial that investigated VEGF levels as a predictor of response to antiangiogenesis agents, particularly bevacizumab (Avastin).
A retrospective analysis of the data present by David W. Miles, MD, suggested that if VEGF-A levels were divided into quartiles the highest quartet level predicted higher response rates to bevacizumab.